POETYK PSO-1 and 2: Long-term efficacy results of deucravacitinib in plaque psoriasis

A follow-up analysis of the POETYK PSO-1 and PSO-2 trials demonstrated maintained efficacy with continued deucravacitinib treatment over 2 years in patients with moderate-to-severe plaque psoriasis, further supporting the use of deucravacitinib in this population.

“Deucravacitinib is a TYK2 inhibitor, uniquely binding to the regulatory domain of TYK2, driving the selectivity of the molecule,” started Prof. Mark Lebwohl (Icahn School of Medicine at Mount Sinai, NY, USA). “It represents the first in a new class of molecules.” The phase 3 POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) trials showed that deucravacitinib is superior to placebo for the treatment of patients with moderate-to-severe plaque psoriasis [1,2]. Participants who completed these trials could enrol in the POETYK PSO-LTE trial (NCT04036435), receiving continued deucravacitinib. Prof. Lebwohl presented data from participants who entered this long-term extension trial after achieving Psoriasis Area and Severity Index (PASI)75 at week 16 in one of the initial trials (n=313) [3].

At week 52, the PASI75 rate dropped from 100% to 86.5%, but it slightly increased again to 89.1% at week 112, as measured by the treatment failure rules (TFR). Similarly, PASI90 rates were maintained at weeks 16, 52, and 112 with rates of 55.9%, 60.6%, and 59.5%, respectively. Also, the static Physician’s Global Assessment (sPGA) 0/1 rate was 70.2% at week 52 and this was maintained at week 112, with 68.8%.

In summary, high clinical activity rates were maintained at week 112 in patients with moderate-to-severe plaque psoriasis who reached PASI75 at week 16 in the POETYK PSO-1 and PSO-2 trials, supporting the use of this once-daily, oral therapy.

1. Armstrong AW, et al. J Am Acad Dermatol. 2023;88(1):29–39.
2. Strober B, et al. J Am Acad Dermatol. 2023;88(1):40–51.
3. Lebwohl MG, et al. Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO-1 AND PSO-2 trials. Session Psoriasis 1, WCD 2023, 3–8 July, Singapore, Singapore.